Abstract
Although introduced in 1938 [16], phenytoin (5,5-diphenylhydantoin) still remains a drug of choice in the treatment of grand mal epilepsy. In addition to continuing investigations aimed at elucidating its mode of action [21], numerous studies over the years have contributed to a much greater appreciation of the dispositional characteristics peculiar to this drug. Recently acquired knowledge obtained from serum phenytoin concentration monitoring [1, 2, 9, 11, 13, 15, 22, 23] has provided pharmacokinetic explanations for the prescribing problems occasionally encountered when a patient’s dosage is altered in an attempt to achieve optimal anti-epileptic therapy. In this paper I shall review some recent pharmacokinetic findings and techniques pertaining to the steady-state serum concentration—dose relationship in phenytoin therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Atkinson, A. J., Shaw, J. M: Pharmacokinetic study of a patient with diphenylhydantoin toxicity. Clin. Pharmacol. Ther. 14, 521–528 (1973).
Bochner, F., Hooper, W. D., Tyrer, J. N., Eadie, M. J.: Effect of dosage increments on blood phenytoin concentrations. J. Neuro1 Neurosurg. Psychiatry 35, 873–876 (1972).
Borga, O., Garle, M., Gutovâ, M.: Identification of 5-(3,4-diphydroxyphenyl-5-)phenlyhydantoin as a metabolite of 5,5-diphenylhydantoin (phenytoin) in rats and man. Pharmacology 7, 129–137 (1972).
Buchthal, F., Svensmark, O., Schiller, P. J.: Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch. Neurol. 2, 624–630 (1960).
Butler, T. C.: The metabolic conversion of 5,5-diphenylhydantoin to 5-(p-hydroxyphenyl)5-phenylhydantoin. J. Pharmacol. Exp. Ther. 119, 1–11 (1957).
Cornish-Bowden, A., Eisenthal, R.: Statistical considerations in the estimation of enzyme kinetic parameters by the direct linear plot and other methods. Biochem. J. 139, 721–730 (1974).
Dowd, J. E., Riggs, D. S.: A comparison of estimates of Michaelis-Menten kinetic constants from various linear transformation. J. Biol. Chem. 240, 863–869 (1965).
Eisenthal, R., Cornish-Bowden, A.: The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem. J. 139, 715–720 (1974).
Garrettson, L. K., Jusko, W. J.: Diphenylhydantoin elimination kinetics in overdosed children. Clin. Pharmacol. Ther. 17, 481–491 (1975).
Gerber, N., Wagner, J. G.: Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menden equation. Res. Commun. Chem. Pathol. Pharmacol. 3, 455–466 (1972).
Kutt, H., McDowell, F.: Management of epilepsy with diphenylhydantoin sodium. J. Am. Med. Assoc. 203, 969–972 (1968).
Ludden, T. M., Allen, J. P., Schneider, L. W., Stavchansky, S. A.: Rate of phenytoin accumulation in man: A simulation study. J. Pharmacokinet. Biopharm. 6, 399–415 (1978).
Ludden, T. M., Allen, J. P., Valutsky, W. A., Vicuna, A. V., Nappi, J. M., Hoffman, S. F., Wallace, J. E., Lalka, D., McNay, J. L.: Individualization of phenytoin dosage regimens. Clin. Pharmacol. Ther. 21, 287–293 (1977).
Martin, E., Tozer, T. N., Sheiner, L. B., Riegelman, S.: The clinical pharmacokinetics of phenytoin. J. Pharmacokinet. Biopharm. 5, 579–596 (1977).
Mawer, G. E., Mullen, P. W., Rodgers, M., Robins, A. J., Lucas, S. B.: Phenytoin dose adjustment in epileptic patients. Br. J. Clin. Pharmacol. 1, 163–168 (1974).
Merritt, H. H., Putnam, T. J.: Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J. Am. Med. Assoc. 111, 1068–1073 (1938).
Michaelis, L., Menten, M. L.: Die Kinetik der Invertinwirkung. Biochem. Z. 49, 333–369 (1913).
Mullen, P. W.: A novel graphical procedure for individualizing phenytoin therapy. Br. J. Clin. Pharmacol. 4, 733P - 734P (1977).
Mullen, P. W.: Optimal phenytoin therapy: A new technique for individualizing dosage. Clin. Parma-col. Ther. 23, 228–232 (1978).
Mullen, P. W., Foster, R. W.: Comparative evaluation of six techniques for determining the MichaelisMenden parameters relating phenytoin dose and steady-state serum concentrations. J. Pharm. Pharmacol. 31, 100–104 (1979).
Perry, J. G., McKinney, L., De Weer, P.: The cellular mode of action of the anti-epileptic drug 5,5-diphenylhydantoin. Nature 272, 271–273 (1978).
Rambeck, B., Boenigk, H. E., Dunlop, A., Mullen, P. W., Wadsworth, J., Richens, A.: Predicting phenytoin dose—a revised nomogram. Therap. Drug Monitor. 1, 325–333 (1979).
Richens, A., Dunlop, A.: Serum phenytoin levels in management of epilepsy. Lancet 2, 247–248 (1975).
Wagner, J. G.: Properties of the Michaelis-Menten equation and its integrated form which are useful in pharmacokinetics. J. Pharmacokinet. Biopharm. 1, 103–121 (1973).
Wagner, J. G.: Time to reach steady-state and predicition of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics. J. Pharmacokinet. Biopharm. 6, 209–225 (1978).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Mullen, P.W. (1980). Techniques for evaluating the steady-state serum concentration—Dose relationship in phenytoin Therapy. In: Rietbrock, N., Woodcock, B.G., Neuhaus, G. (eds) Methods in Clinical Pharmacology. Methods in clinical pharmacology, vol 1. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-14027-6_22
Download citation
DOI: https://doi.org/10.1007/978-3-663-14027-6_22
Publisher Name: Vieweg+Teubner Verlag, Wiesbaden
Print ISBN: 978-3-528-07902-4
Online ISBN: 978-3-663-14027-6
eBook Packages: Springer Book Archive